Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7766 in NMIBC
NCT04109092Phase 1Withdrawn
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of e7766 in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants with Dose-limiting Toxicities at 6 weeks, Number of Participants with Adverse Events and Serious Adverse Events at 42 months and 1 more. Planned start Feb 2020; status: withdrawn.
02
Drugs
e7766
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04109092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109092.